India
The rapid growth of multinational clinical trials in India is supported by a large English-speaking patient population, reliable assistance from the Indian government, and an improving medical and technology infrastructure. One recent study predicted that 15 percent of the world’s clinical trials will be conducted in India by 2011. The clinical trial environment offers numerous benefits for sponsors, including:
- High patient recruitment and retention rates
- Lower costs for medical procedures
- Ability to utilize English as the primary language for data collection and storage
- Alignment with GCP and ICH standards for conducting clinical trials
- Genetic diversity
- Disease profiles similar to Western populations
- Acceptance of local clinical data by the FDA and other regulatory agencies
PAREXEL’s long-standing presence in India allows us to deliver a wide range of high-quality clinical services at every stage of development, from Phase I through commercialization. We have an extensive database of pre-screened sites and investigators, as well as patient databases across a variety of therapeutic areas. We also provide in-depth data services through our global data management team in India, including analyses to determine the safety and efficacy of investigational products in order to gain regulatory approval and local market acceptance.
Click here for a list of PAREXEL’s offices in India.